Nektar Therapeutics | NKTR - Loan Capital


Nektar Therapeutics reported $63.16M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 1.2B Mar/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Baxter International USD 8.62B 852M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 3.82B 840.2M Mar/2026
Dr.Reddys Laboratories INR 12.2B 595M Mar/2026
Eisai JPY 134.78B 12M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 46.67B 77M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Takeda JPY 4.37T 99.51B Mar/2026
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
Xencor USD 82.12M 5.64M Mar/2026